peginterferon alfa 2b (Pegintron)
Jump to navigation
Jump to search
Introduction
Polyethylene-glycol modified interferon alfa 2b.
Tradename: Pegintron (FDA approved 2001)
Indications
- treatment of hepatitis C
- cutaneous melanoma[4]
Dosage
weekly SC injections
Pharmacokinetics
- longer 1/2 life than unmodified IFN-alfa 2b may result in better antiviral activity
Adverse effects
- influenza-like syndrome (fatigue, headache, fever)[3]
- depression, insomnia, irritability
- neutropenia, thrombocytopenia, anemia
- autoimmune thyroiditis[3]
Laboratory
- IFNL3 variation rs12979860 predicts response to PEG-interferon-alpha[6]
Notes
Manufacturer: Schering-Plough
More general terms
More specific terms
Additional terms
Components
References
- ↑ Journal Watch 21(2):14, 2001
- ↑ Prescriber's Letter 8(2):8 2001
- ↑ Jump up to: 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ Jump up to: 4.0 4.1 Deprecated Reference
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ Jump up to: 6.0 6.1 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, telaprevir and IFNL3. https://www.pharmgkb.org/guideline/PA166110235